Extracts of Thesium chinense inhibit SARS-CoV-2 and inflammation in vitro

References

• Attallah NGM, El-Kadem AH, Negm WA, Elekhnawy E, El-Masry TA, Elmongy EI, Altwaijry N, Alanazi AS, Al-Hamoud GA, Ragab AE. 2021. Promising antiviral activity of Agrimonia pilosa phytochemicals against severe acute respiratory syndrome coronavirus 2 supported with in vivo mice study. Pharmaceuticals-Base. 14(12):1313. doi: 10.3390/ph14121313.
   Web of Science ®Google Scholar
• Chen K, Chen H. 2020. Traditional Chinese medicine for combating COVID-19. Front Med. 14(5):529–532. doi: 10.1007/s11684-020-0802-9.
   PubMed Web of Science ®Google Scholar
• Cheng PC, Wong G. 1996. Honey bee propolis: prospects in medicine. Bee World. 77(1):8–15. doi: 10.1080/0005772X.1996.11099278.
   Web of Science ®Google Scholar
• Chen WQ, Wang S, You QH. 2021. Application of LeDock and PyMOL software in the course teaching of natural product chemistry: a case study of traditional Chinese medicine in treating novel coronavirus pneumonia (COVID-19). Chem Educ. 42(24):97–100.
   Google Scholar
• Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. 2003. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet. 361(9374):2045–2046. doi: 10.1016/s0140-6736(03)13615-x.
   PubMed Web of Science ®Google Scholar
• Davies-Bolorunduro OF, Fowora MA, Amoo OS, Adeniji E, Osuolale KA, Oladele O, Onuigbo TI, Obi JC, Oraegbu J, Ogundepo O, et al. 2022. Evaluation of respiratory tract bacterial co-infections in SARS-CoV-2 patients with mild or asymptomatic infection in Lagos, Nigeria. Bull Natl Res Cent. 46(1):115. doi: 10.1186/s42269-022-00811-2.
   PubMedGoogle Scholar
• De Clercq E. 2019. New nucleoside analogues for the treatment of hemorrhagic fever virus infections. Chem Asian J. 14(22):3962–3968. doi: 10.1002/asia.201900841.
   PubMed Web of Science ®Google Scholar
• Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz TH, Madduri D, Stock A, et al. 2020. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 26(10):1636–1643. doi: 10.1038/s41591-020-1051-9.
   PubMed Web of Science ®Google Scholar
• Dorner T, Kay J. 2015. Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol. 11(12):713–724. doi: 10.1038/nrrheum.2015.110.
   PubMed Web of Science ®Google Scholar
• El-Hilaly J, Amarouch MY, Morel N, Lyoussi B, Quetin-Leclercq J. 2021. Ajuga iva water extract antihypertensive effect on stroke-prone spontaneously hypertensive rats, vasorelaxant effects ex vivo and in vitro activity of fractions. J Ethnopharmacol. 270:113791. doi: 10.1016/j.jep.2021.113791.
   PubMed Web of Science ®Google Scholar
• Focosi D, Maggi F, McConnell S, Casadevall A. 2022. Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis. Antiviral Res. 198:105247. doi: 10.1016/j.antiviral.2022.105247.
   PubMed Web of Science ®Google Scholar
• Fung TS, Liu DX. 2019. Human Coronavirus: host-pathogen interaction. Annu Rev Microbiol. 73(1):529–557. doi: 10.1146/annurev-micro-020518-115759.
   PubMed Web of Science ®Google Scholar
• Gandhi S, Klein J, Robertson A, Pena-Hernandez MA, Lin MJ, Roychoudhury P, Lu PW, Fournier J, Ferguson D, Bakhash SAM, et al. 2022. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. Nat Commun. 13(1):1547. doi: 10.1038/s41467-022-29104-y.
   PubMed Web of Science ®Google Scholar
• Gupta RK, George R, Nguyen-Van-Tam JS. 2008. Bacterial pneumonia and pandemic influenza planning. Emerg Infect Dis. 14(8):1187–1192. doi: 10.3201/eid1408.070751.
   PubMed Web of Science ®Google Scholar
• Kalliolias GD, Ivashkiv LB. 2016. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 12(1):49–62. doi: 10.1038/nrrheum.2015.169.
   PubMed Web of Science ®Google Scholar
• Kerber R, Lorenz E, Duraffour S, Sissoko D, Rudolf M, Jaeger A, Cisse SD, Camara AM, Miranda O, Castro CM, et al. 2019. Laboratory findings, compassionate use of favipiravir, and outcome in patients with Ebola virus disease, Guinea, 2015-A retrospective observational study. J Infect Dis. 220(2):195–202. doi: 10.1093/infdis/jiz078.
   PubMed Web of Science ®Google Scholar
• Kirtipal N, Bharadwaj S, Kang SG. 2020. From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses. Infect Genet Evol. 85:104502. doi: 10.1016/j.meegid.2020.104502.
   PubMed Web of Science ®Google Scholar
• Liao Q, Chen Z, Tao Y, Zhang B, Wu X, Yang L, Wang Q, Wang Z. 2021. An integrated method for optimized identification of effective natural inhibitors against SARS-CoV-2 3CLpro. Sci Rep. 11(1):22796. doi: 10.1038/s41598-021-02266-3.
   PubMed Web of Science ®Google Scholar
• Li GH, Fang KL, Yang K, Cheng XP, Wang XN, Shen T, Lou HX. 2021. Thesium chinense Turcz.: An ethnomedical, phytochemical and pharmacological review. J Ethnopharmacol. 273:113950. doi: 10.1016/j.jep.2021.113950.
   PubMed Web of Science ®Google Scholar
• Liu C, Li XT, Cheng RR, Han ZZ, Yang L, Song ZC, Wang ZT. 2018. Anti-oral common pathogenic bacterial active acetylenic acids from Thesium chinense Turcz. J Nat Med. 72(2):433–438. doi: 10.1007/s11418-018-1180-3.
   PubMed Web of Science ®Google Scholar
• Liu YS, Pan L, Qi KZ, Jiang LK. 2006. Sensitivity test of effective extracts of Thesium chinense Turcz to seven types of bacteria. Guizhou Pharm. 06:564–566.
   Google Scholar
• Liu H, Ye F, Sun Q, Liang H, Li C, Li S, Lu R, Huang B, Tan W, Lai L. 2021. Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro. J Enzyme Inhib Med Chem. 36(1):497–503. doi: 10.1080/14756366.2021.1873977.
   PubMed Web of Science ®Google Scholar
• Li X, Xu ZX, Ming YL. 2020. Application of Chinese herbal medicine in the prevention and treatment of COVID-19. Subtro Plant Sci. 49(02):83–92.
   Google Scholar
• Mo Y, Fisher D. 2016. A review of treatment modalities for Middle East Respiratory Syndrome. J Antimicrob Chemother. 71(12):3340–3350. doi: 10.1093/jac/dkw338.
   PubMed Web of Science ®Google Scholar
• Muller MP, Dresser L, Raboud J, McGeer A, Rea E, Richardson SE, Mazzulli T, Loeb M, Louie M, Canadian SRN; Canadian SARS Research Network. 2007. Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome. Pharmacotherapy. 27(4):494–503. doi: 10.1592/phco.27.4.494.
   PubMed Web of Science ®Google Scholar
• Pan B, Fang S, Zhang J, Pan Y, Liu H, Wang Y, Li M, Liu L. 2020. Chinese herbal compounds against SARS-CoV-2: puerarin and quercetin impair the binding of viral S-protein to ACE2 receptor. Comput Struct Biotechnol J. 18:3518–3527. doi: 10.1016/j.csbj.2020.11.010.
   PubMed Web of Science ®Google Scholar
• Parveen Z, Deng Y, Saeed MK, Dai R, Ahamad W, Yu YH. 2007. Antiinflammatory and analgesic activities of Thesium chinense Turcz extracts and its major flavonoids, kaempferol and kaempferol-3-O-glucoside. Yakugaku Zasshi. 127(8):1275–1279. doi: 10.1248/yakushi.127.1275.
   PubMed Web of Science ®Google Scholar
• Peng Y, Du N, Lei Y, Dorje S, Qi J, Luo T, Gao GF, Song H. 2020. Structures of the SARS-CoV-2 nucleocapsid and their perspectives for drug design. Embo J. 39(20):e105938.
   PubMed Web of Science ®Google Scholar
• Pruijssers AJ, George AS, Schafer A, Leist SR, Gralinksi LE, Dinnon KH, 3rd, Yount BL, Agostini ML, Stevens LJ, Chappell JD, et al. 2020. Remdesivir Inhibits SARS-CoV-2 in human lung cells and Chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. Cell Rep. 32(3):107940. doi: 10.1016/j.celrep.2020.107940.
   PubMed Web of Science ®Google Scholar
• Pum A, Ennemoser M, Adage T, Kungl AJ. 2021. Cytokines and chemokines in SARS-CoV-2 infections-therapeutic strategies targeting cytokine storm. Biomolecules. 11(1):91. doi: 10.3390/biom11010091.
   PubMed Web of Science ®Google Scholar
• Rattanaburi S, Sawaswong V, Chitcharoen S, Sivapornnukul P, Nimsamer P, Suntronwong N, Puenpa J, Poovorawan Y, Payungporn S. 2022. Bacterial microbiota in upper respiratory tract of COVID-19 and influenza patients. Exp Biol Med (Maywood). 247(5):409–415. doi: 10.1177/15353702211057473.
   PubMed Web of Science ®Google Scholar
• Rossi JF, Lu ZY, Jourdan M, Klein B. 2015. Interleukin-6 as a therapeutic target. Clin Cancer Res. 21(6):1248–1257. doi: 10.1158/1078-0432.CCR-14-2291.
   PubMed Web of Science ®Google Scholar
• Shao L, Sun Y, Liang J, Li M, Li X. 2020. Decolorization affects the structural characteristics and antioxidant activity of polysaccharides from Thesium chinense Turcz: comparison of activated carbon and hydrogen peroxide decolorization. Int J Biol Macromol. 155:1084–1091. doi: 10.1016/j.ijbiomac.2019.11.074.
   PubMed Web of Science ®Google Scholar
• Sun Z, Li Q, Hou R, Sun H, Tang Q, Wang H, Hao Z, Kang S, Xu T, Wu S. 2019. Kaempferol-3-O-glucorhamnoside inhibits inflammatory responses via MAPK and NF-kappaB pathways in vitro and in vivo. Toxicol Appl Pharmacol. 364:22–28. doi: 10.1016/j.taap.2018.12.008.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang N, Yang L, Song XQ. 2022. Bioactive natural products in COVID-19 therapy. Front Pharmacol. 13:926507. doi: 10.3389/fphar.2022.926507.
   PubMed Web of Science ®Google Scholar
• Wang Z, Yang L. 2022. In the age of Omicron variant: paxlovid raises new hopes of COVID-19 recovery. J Med Virol. 94(5):1766–1767. doi: 10.1002/jmv.27540.
   PubMed Web of Science ®Google Scholar
• Wang ZL, Yang LY. 2021. Chinese herbal medicine: fighting SARS-CoV-2 infection on all fronts. J Ethnopharmacol. 270:113869. doi: 10.1016/j.jep.2021.113869.
   PubMed Web of Science ®Google Scholar
• Wang Z, Yang L, Song XQ. 2022. Oral GS-441524 derivatives: next-generation inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase. Front Immunol. 13:1015355. doi: 10.3389/fimmu.2022.1015355.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, et al. 2020. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 395(10236):1569–1578. doi: 10.1016/S0140-6736(20)31022-9.
   PubMed Web of Science ®Google Scholar
• Westblade LF, Simon MS, Satlin MJ. 2021. Bacterial coinfections in Coronavirus disease 2019. Trends Microbiol. 29(10):930–941. doi: 10.1016/j.tim.2021.03.018.
   PubMed Web of Science ®Google Scholar
• Williamson BN, Feldmann F, Schwarz B, Meade-White K, Porter DP, Schulz J, van Doremalen N, Leighton I, Yinda CK, Perez-Perez L, et al. 2020. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature. 585(7824):273–276. doi: 10.1038/s41586-020-2423-5.
   PubMed Web of Science ®Google Scholar
• Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X, et al. 2020. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 117(20):10970–10975. doi: 10.1073/pnas.2005615117.
   PubMed Web of Science ®Google Scholar
• Yang L, Li Y-T, Miao J, Wang L, Fu H, Li Q, Wen W-B, Zhang Z-Y, Song R-W, Liu X-G, et al. 2020. Network pharmacology studies on the effect of Chai-Ling decoction in coronavirus disease 2019. Trad Chinese Med. 5:145–159.
   Google Scholar
• Yang L, Wang Z. 2021. Natural products, alone or in combination with FDA-approved drugs, to treat COVID-19 and lung cancer. Biomedicines. 9(6):689. doi: 10.3390/biomedicines9060689.
   PubMed Web of Science ®Google Scholar
• Zheng M, Karki R, Williams EP, Yang D, Fitzpatrick E, Vogel P, Jonsson CB, Kanneganti TD. 2021. TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat Immunol. 22(7):829–838. doi: 10.1038/s41590-021-00937-x.
   PubMed Web of Science ®Google Scholar